Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Streptococcus pneumoniae type 10A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Streptococcus pneumoniae type 10A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a component of pneumococcal conjugate vaccines, such as Prevnar 20. It consists of the purified capsular polysaccharide from Streptococcus pneumoniae serotype 10A chemically linked (conjugated) to the non-toxic mutant diphtheria toxin carrier protein, CRM197. This glycoconjugation enhances immunogenicity by inducing a T-cell dependent immune response, resulting in robust and long-lasting immunity even in young children and immunocompromised individuals. The primary indication is active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae, including conditions like pneumococcal pneumonia and bacteremia[3][4][8]. The vaccine is administered via intramuscular injection.
- Brand names
- Prevnar 20Prevnar20Prevnar-20
- Other names
- Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccinePNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A CONJUGATED TO CRM197
02
Targets
10A CPS (Streptococcus pneumoniae serotype 10A capsular polysaccharide)
Beyond the preview
Go deeper on Streptococcus pneumoniae type 10A capsular polysaccharide diphtheria CRM197 protein conjugate antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Streptococcus pneumoniae type 10A capsular polysaccharide diphtheria CRM197 protein conjugate antigen.